Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Turkish Journal of Biology = Turk Biyoloji Dergisi|January 7, 2026
Identification of epigenetic monotherapy candidates in taxane-resistant CRPCBuse Cevatemre, İpek Bulut, Ezgi Karyemez, et al.Turkish Journal of Biology = Turk Biyoloji Dergisi|July 18, 2025
Butyrylcholinesterase (BChE) downregulation in taxane resistance: implications for prostate cancerBuse Cevatemre, Arda Işiklar, İpek Bulut, et al.Cell Communication and Signaling : CCS|December 19, 2025
Menin-driven mTOR signaling sustains taxane resistance in CRPC and reveals a targetable vulnerability for combination therapyIpek Bulut, Buse Cevatemre, Neslihan Yuksel-Catal, et al.Chemmedchem|April 15, 2021
Understanding the Potential In Vitro Modes of Action of Bis(β-diketonato) Oxovanadium(IV) ComplexesBaris Sergi, Ipek Bulut, Ying Xia, et al.Cell Death & Disease|February 12, 2024
Exploiting epigenetic targets to overcome taxane resistance in prostate cancerBuse Cevatemre, Ipek Bulut, Beyza Dedeoglu, et al.Cell Death Discovery|April 17, 2026
Nicotinamide N-methyltransferase as a therapeutic target in taxane-resistant castration-resistant prostate cancerBuse Cevatemre, Ezgi Karyemez, Ipek Bulut, et al.Cancers|December 11, 2022
Dual LSD1 and HDAC6 Inhibition Induces Doxorubicin Sensitivity in Acute Myeloid Leukemia CellsIpek Bulut, Adam Lee, Buse Cevatemre, et al.Dalton Transactions (Cambridge, England : 2003)|December 8, 2020
Cu(ii) and V(iv)O complexes with tri- or tetradentate ligands based on (2-hydroxybenzyl)-l-alanines reveal promising anticancer therapeutic potentialNádia Ribeiro, Ipek Bulut, Buse Cevatemre, et al.Journal of Inorganic Biochemistry|August 8, 2022
Solution chemical properties and anticancer potential of 8-hydroxyquinoline hydrazones and their oxidovanadium(IV) complexesNádia Ribeiro, Ipek Bulut, Vivien Pósa, et al.Frontiers in Chemistry|April 7, 2023
Promising anticancer agents based on 8-hydroxyquinoline hydrazone copper(II) complexesNádia Ribeiro, Ipek Bulut, Baris Sergi, et al.Pageof 2